Abstract 1946
Background
Bone marrow aspiration and biopsy at presentation is important to demonstrate the phase of the disease, to provide material for cytogenetic studies and to demonstrate the myelofibrosis, which have prognostic and therapeutic implications. In the current era of molecular diagnostics, the role of bone marrow examination is questionable. The present study was designed to identify the role of bone marrow examination on phase migration, karyotyping and myelofibrosis.
Methods
Data of newly diagnosed CML patients seen between January 2013 and June 2018 was retrospectively analysed. CML was confirmed by demonstration of BCR-ABL fusion gene by PCR or FISH. Patients were stratified into chronic phase (CP), accelerated phase (AP) and blast phase (BP) according to WHO diagnostic criteria (2016).
Results
Of 749 patients, 541 patients had evaluable data. The male female ratio was 1.52:1 The median age at presentation was 37 years (range, 9-80 years). According to EUTOS risk stratification, 406 (75.1%) patients were low risk and 135(24.9%) were high risk. Based on bone marrow blasts criterion, phase migration occurred in 16 (2.9%). Of these 16 patients, phase migration from CP to AP, CP to BP and AP to BP were seen in 8 (50%), 4(25%) and 4 (25%) patients, respectively. Data on karyotyping was available in 195 (36%) patients. Of 195 patients, additional cytogenetic abnormalities were detected in 30 (15.3%) which includes, major route abnormalities in 11 (5.6%) patients. Of these 11 patients, 6 patients were in CP, 4 patients were in AP and 1 patient in BP. Myelofibrosis was demonstrated in 264 (48.7%) patients of which grade 1, grade 2, grade 3 and grade 4 were seen in 72 (13.3%), 100 (18.5%), 70 (12.9%); 20 (3.7%) patients respectively.
Conclusions
Bone marrow examination at presentation in CML patients results in phase migration, provides adequate material for cytogenetic studies and demonstrates presence of myelofibrosis. Hence, bone marrow examination is indispensable in newly diagnosed CML patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Nizam’s Institute of Medical Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1496 - Randomized, double-blind, cross-over Phase I study comparing pharmacokinetics, pharmacodynamics, safety and immunogenicity of a biosimilar pegfilgrastim with EU and US references
Presenter: Maria Velinova
Session: Poster Display session 1
Resources:
Abstract
3993 - Prophylaxis with Lipegfilgrastim in patients with primary breast cancer receiving dose dense chemotherapy: results from the German NIS NADENS
Presenter: Marion Kiechle
Session: Poster Display session 1
Resources:
Abstract
3471 - Randomized phase 2 trial evaluating the safety of peripherally inserted central catheters vs implanted port catheters during adjuvant chemotherapy in early breast cancer patients.
Presenter: Florian Clatot
Session: Poster Display session 1
Resources:
Abstract
1327 - Simultaneous intravenous fluid infusion to prevent oxaliplatin infusion-related venous pain
Presenter: Stefan Van Ravensteijn
Session: Poster Display session 1
Resources:
Abstract
5004 - Clinical practice evaluation of opioids induced constipation management in cancer patients: The EIO-Praxis project.
Presenter: Enrique Aranda Aguilar
Session: Poster Display session 1
Resources:
Abstract
2222 - Analysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxative-inadequate response.
Presenter: Manuel Cobo Dols
Session: Poster Display session 1
Resources:
Abstract
5556 - Consensus on strategies in the management of opioid-induced constipation in cancer patients
Presenter: Regina Girones Sarrio
Session: Poster Display session 1
Resources:
Abstract
3913 - Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
Presenter: Yanni Lou
Session: Poster Display session 1
Resources:
Abstract
2208 - A prospective study about the complementary medicine among patients with cancers
Presenter: Wala Ben Kridis
Session: Poster Display session 1
Resources:
Abstract
1082 - Prevalence and management of Potentially Inappropriate Medication use and Potential Omissions in Medication in older cancer patients - the PIM POM study
Presenter: Fianne van Loveren
Session: Poster Display session 1
Resources:
Abstract